{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:48:46Z","timestamp":1790999326638,"version":"4.1.0"},"reference-count":264,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish Government","award":["PI17\/01931"],"award-info":[{"award-number":["PI17\/01931"]}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2016\/75959-R"],"award-info":[{"award-number":["SAF2016\/75959-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIBERNED","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"crossref","award":["SAF2015-68580-C2-1-R"],"award-info":[{"award-number":["SAF2015-68580-C2-1-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bcp.2018.08.016","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T13:00:03Z","timestamp":1534510803000},"page":"67-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"special_numbering":"C","title":["Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system"],"prefix":"10.1016","volume":"157","author":[{"given":"Maria S.","family":"Aymerich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Abellanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Tolon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidre","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.08.016_b0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuron.2011.06.031","article-title":"Selective neuronal vulnerability in neurodegenerative diseases from stressor thresholds to degeneration","volume":"71","author":"Saxena","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2018.08.016_b0010","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.08.016_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40035-017-0096-2","article-title":"Disease modification and Neuroprotection in neurodegenerative disorders","volume":"6","author":"Cummings","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.bcp.2018.08.016_b0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neuroscience.2014.03.045","article-title":"Linking pathways in the developing and aging brain with neurodegeneration","volume":"269","author":"Kovacs","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.016_b0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrn3876","article-title":"Endocannabinoid signalling and the deteriorating brain","volume":"16","author":"Di Marzo","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0030","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14382","article-title":"The biomedical challenge of neurodegenerative disorders an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0035","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2018.08.016_b0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and Tau","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b0045","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/00207454.2013.804821","article-title":"Establishment of experimental models for Alzheimer\u2019s disease research","volume":"123","author":"Li","year":"2013","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pneurobio.2012.03.005","article-title":"Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia","volume":"97","author":"Ferrer","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bcp.2018.08.016_b0055","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.1228541","article-title":"Preventing Alzheimer\u2019s disease","volume":"337","author":"Selkoe","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bcp.2018.08.016_b0060","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease","volume":"366","author":"Howard","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.08.016_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-2010-1414","article-title":"Neuroinflammation in Alzheimer\u2019s disease mechanisms, pathologic consequences, and potential for therapeutic manipulation","volume":"21","author":"Hensley","year":"2010","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-3-319-20825-1_8","article-title":"endocannabinoids and neurodegenerative disorders Parkinson\u2019s disease, Huntington\u2019s chorea, Alzheimer\u2019s disease, and others","author":"Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Handb. Exp. Pharmacol.,"},{"key":"10.1016\/j.bcp.2018.08.016_b0075","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0306-4522(94)90511-8","article-title":"Cannabinoid receptor binding and messenger RNA expression in human brain an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer\u2019s brains","volume":"63","author":"Westlake","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.016_b0080","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuint.2010.10.010","article-title":"Intact cannabinoid CB1 receptors in the Alzheimer\u2019s disease cortex","volume":"57","author":"Lee","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bcp.2018.08.016_b0085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.euroneuro.2013.10.002","article-title":"In vivo type 1 cannabinoid receptor availability in Alzheimer\u2019s disease","volume":"24","author":"Ahmad","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0090","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3233\/JAD-140492","article-title":"Type-1 cannabinoid receptor activity during Alzheimer\u2019s disease progression","volume":"42","author":"Manuel","year":"2014","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/JAD-131961","article-title":"Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the A\u03b2PPswe\/PS1\u0394E9 mouse model of Alzheimer\u2019s disease","volume":"42","author":"Maroof","year":"2014","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuroscience.2017.08.008","article-title":"Increase in cortical endocannabinoid signaling in a rat model of basal forebrain cholinergic dysfunction","volume":"362","author":"Llorente-Ovejero","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.016_b0105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2174\/1871527311211080014","article-title":"Functional autoradiography shows unaltered cannabinoid CB1 receptor signalling in hippocampus and cortex of APP\/PS1 transgenic mice","volume":"11","author":"K\u00e4rkk\u00e4ine","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.bcp.2018.08.016_b0110","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer \u2019 s disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1476-5381.2010.00729.x","article-title":"CB2 a cannabinoid receptor with an identity crisis","volume":"160","author":"Atwood","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0120","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer\u2019s disease pathology by cannabinoids neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ram\u00edrez","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129618","article-title":"Cannabinoid CB2 receptors in a mouse model of A\u03b2 amyloidosis immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation","volume":"10","author":"Savonenko","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2018.08.016_b0130","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00259-016-3457-7","article-title":"Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer\u2019s disease","volume":"43","author":"Ahmad","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"10.1016\/j.bcp.2018.08.016_b0135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12974-018-1174-9","article-title":"Cannabinoid CB2 receptors in mouse brain relevance for Alzheime\u0155s disease","volume":"15","author":"L\u00f3pez","year":"2018","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.bcp.2018.08.016_b0140","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cell.2013.10.042","article-title":"\u03949-THC-caused synaptic and memory impairments are mediated through COX-2 signaling","volume":"155","author":"Chen","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2018.08.016_b0145","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1016\/j.neurobiolaging.2015.08.003","article-title":"Endocannabinoid regulation of amyloid-induced neuroinflammation","volume":"36","author":"V\u00e1zquez","year":"2015","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.bcp.2018.08.016_b0150","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.neurobiolaging.2011.03.012","article-title":"An amyloid \u03b242-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer\u2019s disease","volume":"33","author":"Jung","year":"2012","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.bcp.2018.08.016_b0155","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/brain\/awr046","article-title":"Molecular reorganization of endocannabinoid signalling in Alzheimer\u2019s disease","volume":"134","author":"Mulder","year":"2011","journal-title":"Brain."},{"key":"10.1016\/j.bcp.2018.08.016_b0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-511X-8-2","article-title":"Endocannabinoids in Alzheimer\u2019s disease and their impact on normative cognitive performance a case-control and cohort study","volume":"8","author":"Koppel","year":"2009","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0165","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-142349","article-title":"Elevation of plasma 2-Arachidonoylglycerol Levels in Alzheimer\u2019s disease patients as a potential protective mechanism against neurodegenerative decline","volume":"46","author":"Altamura","year":"2015","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0170","article-title":"Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease","volume":"7","author":"D\u2019Addario","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2018.08.016_b0175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3940(02)00936-9","article-title":"Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide","volume":"332","author":"Milton","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuroscience.2011.01.024","article-title":"Endocannabinoid 2-arachidonoylglycerol protects neurons against \u03b2-amyloid insults","volume":"178","author":"Chen","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.016_b0185","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuro.2011.12.015","article-title":"Contrasting protective effects of cannabinoids against oxidative stress and amyloid-\u03b2 evoked neurotoxicity in vitro","volume":"33","author":"Harvey","year":"2012","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bcp.2018.08.016_b0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10571-013-9984-x","article-title":"Cannabinoid effects on \u03b2 amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro","volume":"34","author":"Janefjord","year":"2014","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2018.08.016_b0195","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","article-title":"Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells","volume":"89","author":"Iuvone","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2018.08.016_b0200","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-2012-111862","article-title":"CB1 agonist ACEA protects neurons and reduces the cognitive impairment of A\u03b2PP\/PS1 mice","volume":"30","author":"Aso","year":"2012","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0205","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3233\/JAD-140093","article-title":"The potential therapeutic effects of THC on Alzheimer\u2019s disease","volume":"42","author":"Cao","year":"2014","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0210","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00018-006-6037-3","article-title":"Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo effect of pharmacological elevation of endocannabinoid levels","volume":"63","author":"van der Stelt","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2018.08.016_b0215","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000338494","article-title":"CB1 cannabinoid receptor activation rescues amyloid \u03b2-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones","volume":"29","author":"Haghani","year":"2012","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2018.08.016_b0220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.nlm.2016.07.030","article-title":"Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(\u03b1) and (m)VD-hemopressin(\u03b1) on memory in novel object and object location recognition tasks in normal young and A\u03b21-42-treated mice","author":"Zhang","year":"2016","journal-title":"Neurobiol. Learn. Mem. 134 Pt B"},{"key":"10.1016\/j.bcp.2018.08.016_b0225","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2012.06.011","article-title":"Activation of the CB2 receptor system reverses amyloid-induced memory deficiency","volume":"34","author":"Wu","year":"2013","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.bcp.2018.08.016_b0230","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer\u2019s disease","volume":"79","author":"Mart\u00edn-Moreno","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0235","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.neuropharm.2012.05.013","article-title":"WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-\u03b3 pathway","volume":"63","author":"Fakhfouri","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b0240","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-9-8","article-title":"Prolonged oral cannabinoid administration prevents neuroinflammation, lowers \u03b2-amyloid levels and improves cognitive performance in Tg APP 2576 mice","volume":"9","author":"Mart\u00edn-Moreno","year":"2012","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.bcp.2018.08.016_b0245","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3233\/JAD-130137","article-title":"CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A\u03b2PP\/PS1 mice","volume":"35","author":"Aso","year":"2013","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0250","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice","volume":"42","author":"Cheng","year":"2014","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0255","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s00213-014-3478-5","article-title":"Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe\/PS1\u0394E9 mice","volume":"231","author":"Cheng","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b0260","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3233\/JAD-141014","article-title":"Cannabis-based medicine reduces multiple pathological processes in A\u03b2PP\/PS1 mice","volume":"43","author":"Aso","year":"2015","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0265","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3233\/JAD-160533","article-title":"Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model","volume":"54","author":"Aso","year":"2016","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0270","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ptr.5095","article-title":"Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPAR\u03b3 involvement","volume":"28","author":"Scuderi","year":"2014","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bcp.2018.08.016_b0275","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainres.2009.05.098","article-title":"The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages","volume":"1283","author":"Tol\u00f3n","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2018.08.016_b0280","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mcn.2013.06.004","article-title":"Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier","volume":"56","author":"Bachmeier","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2017.05.044","article-title":"Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer\u2019s disease","volume":"811","author":"Wu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0290","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.celrep.2012.05.001","article-title":"A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer\u2019s disease","volume":"1","author":"Piro","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2018.08.016_b0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2119\/molmed.2013.00140.revised","article-title":"CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer\u2019s disease","volume":"20","author":"Koppel","year":"2014","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2018.08.016_b0300","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.neurobiolaging.2014.09.019","article-title":"Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer\u2019s disease mouse model","volume":"36","author":"Schm\u00f6le","year":"2015","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.bcp.2018.08.016_b0305","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-150913","article-title":"Cannabinoid receptor 2 Participates in Amyloid-\u03b2 processing in a mouse model of Alzheimer\u2019s Disease but plays a minor role in the therapeutic properties of a cannabis-based medicine","volume":"51","author":"Aso","year":"2016","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0310","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2174\/156720510791050948","article-title":"Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer\u2019s disease mouse model","volume":"7","author":"Chen","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bcp.2018.08.016_b0315","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1016\/j.neurobiolaging.2013.05.027","article-title":"Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer\u2019s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition","volume":"34","author":"Stumm","year":"2013","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.bcp.2018.08.016_b0320","doi-asserted-by":"crossref","unstructured":"F.I. Aso E, Andr\u00e9s-Benito P, Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model, Biochem. Pharmacol. In press (2018).","DOI":"10.1016\/j.bcp.2018.08.007"},{"key":"10.1016\/j.bcp.2018.08.016_b0325","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.phrs.2018.02.009","article-title":"Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimer\u2019s disease-like mice overexpressing the human mutant amyloid precursor protein","volume":"130","author":"Maccarrone","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2018.08.016_b0330","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00109-005-0025-1","article-title":"The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt\/beta-catenin pathway rescue in PC12 cells","volume":"84","author":"Esposito","year":"2006","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.bcp.2018.08.016_b0335","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.neulet.2006.06.012","article-title":"CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons","volume":"404","author":"Esposito","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b0340","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders important new clinical applications for this phytocannabinoid?","volume":"75","author":"Fern\u00e1ndez-Ruiz","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0345","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/mol.118.111864","article-title":"Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons","volume":"94","author":"Straiker","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0350","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-130050","article-title":"Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy","volume":"35","author":"Casarejos","year":"2013","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000362689","article-title":"\u03b2-Caryophyllene ameliorates the Alzheimer-like phenotype in APP\/PS1 Mice through CB2 receptor activation and the PPAR\u03b3 pathway","volume":"94","author":"Cheng","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b0360","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fnins.2016.00243","article-title":"CB2 Cannabinoid Receptor As Potential Target against Alzheimer\u2019s Disease","volume":"10","author":"Aso","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0365","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fnins.2017.00030","article-title":"Cannabinoid receptor 2 signaling in neurodegenerative disorders from pathogenesis to a promising therapeutic target","volume":"11","author":"Cassano","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0370","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1007\/s12035-017-0689-x","article-title":"Alleviation of neuropathology by inhibition of monoacylglycerol lipase in APP transgenic mice lacking CB2 receptors","volume":"55","author":"Zhang","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2018.08.016_b0375","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.celrep.2012.09.030","article-title":"Monoacylglycerol lipase is a therapeutic target for Alzheimer\u2019s disease","volume":"2","author":"Chen","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2018.08.016_b0380","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1209200","article-title":"Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation","volume":"334","author":"Nomura","year":"2011","journal-title":"Science (80-.)"},{"key":"10.1016\/j.bcp.2018.08.016_b0385","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1742-2094-9-79","article-title":"The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation","volume":"9","author":"Murphy","year":"2012","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.bcp.2018.08.016_b0390","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1021\/ml200313p","article-title":"The first dual ChE\/FAAH inhibitors new perspectives for Alzheimer\u2019s disease?","volume":"3","author":"Rampa","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b0395","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1021\/acs.jmedchem.6b00609","article-title":"Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE) Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer\u2019s Disease Agents","volume":"59","author":"Montanari","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2018.08.016_b0400","first-page":"1240","article-title":"Oxidative stress and mitochondrial dysfunction in Alzheimer\u2019s disease","volume":"2014","author":"Wang","year":"1842","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0405","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1586\/ern.10.74","article-title":"Antioxidant approaches for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Lee","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bcp.2018.08.016_b0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2018.08.016_b0415","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fphar.2017.00744","article-title":"Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors","volume":"8","author":"Mart\u00ednez-Pinilla","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0420","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.redox.2016.12.029","article-title":"Cannabidiol attenuates OGD\/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons","volume":"11","author":"Sun","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2018.08.016_b0425","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1590\/1516-4446-2012-0886","article-title":"Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain","volume":"35","author":"Valvassori","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.bcp.2018.08.016_b0430","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12035-013-8514-7","article-title":"Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload implications for neuroprotection","volume":"49","author":"da Silva","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2018.08.016_b0435","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s12031-015-0545-2","article-title":"Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria","volume":"56","author":"Singh","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0440","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.toxlet.2014.09.002","article-title":"Cannabinoid-induced changes in respiration of brain mitochondria","volume":"231","author":"Fi\u0161ar","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b0445","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/mp060066m","article-title":"A molecular link between the active component of marijuana and Alzheimer\u2019s disease pathology","volume":"3","author":"Eubanks","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2018.08.016_b0450","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejmech.2013.11.026","article-title":"Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer\u2019s disease","volume":"73","author":"Gonz\u00e1lez-Naranjo","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2018.08.016_b0455","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1073\/pnas.86.23.9584","article-title":"Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker","volume":"86","author":"Feigenbaum","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2018.08.016_b0460","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0304-3940(93)90555-Y","article-title":"The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain","volume":"162","author":"Nadler","year":"1993","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b0465","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00001756-199312000-00013","article-title":"HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture","volume":"5","author":"Eshhar","year":"1993","journal-title":"NeuroReport"},{"key":"10.1016\/j.bcp.2018.08.016_b0470","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bcp.2018.08.016_b0475","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1073\/pnas.89.9.3825","article-title":"Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells","volume":"89","author":"Mackie","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2018.08.016_b0480","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1152\/jn.1997.78.1.43","article-title":"Cannabinoids inhibit N- and P\/Q-type calcium channels in cultured rat hippocampal neurons","volume":"78","author":"Twitchell","year":"1997","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.bcp.2018.08.016_b0485","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.neuropharm.2005.01.005","article-title":"Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores","volume":"48","author":"Zhuang","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b0490","doi-asserted-by":"crossref","first-page":"38543","DOI":"10.1074\/jbc.M110.162040","article-title":"Endocannabinoids prevent \u03b2-amyloid-mediated lysosomal destabilization in cultured neurons","volume":"285","author":"Noonan","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.08.016_b0495","doi-asserted-by":"crossref","first-page":"34709","DOI":"10.1074\/jbc.M112.350678","article-title":"The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-\u03b2 and in the cortex of aged rats","volume":"287","author":"Tanveer","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.08.016_b0500","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fnins.2016.00422","article-title":"Vascular dysfunction in a transgenic model of Alzheimer\u2019s disease effects of CB1R and CB2R cannabinoid agonists","volume":"10","author":"Navarro-Dorado","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0505","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.neuropharm.2016.03.015","article-title":"Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer\u2019s disease","volume":"110","author":"K\u00f6falvi","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b0510","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease","volume":"12","author":"Volicer","year":"1997","journal-title":"Int. J. Geriatr. Psychiatry."},{"key":"10.1016\/j.bcp.2018.08.016_b0515","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b0520","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/gps.1828","article-title":"The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation","volume":"23","author":"Passmore","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry."},{"key":"10.1016\/j.bcp.2018.08.016_b0525","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia. A randomized controlled trial","volume":"84","author":"van den Elsen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2018.08.016_b0530","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jagp.2015.07.011","article-title":"Tetrahydrocannabinol in behavioral disturbances in dementia. a crossover randomized controlled trial","volume":"23","author":"van den Elsen","year":"2015","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.bcp.2018.08.016_b0535","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0269881116665357","article-title":"Effects of tetrahydrocannabinol on balance and gait in patients with dementia. A randomised controlled crossover trial","volume":"31","author":"van den Elsen","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0540","first-page":"CD007204","article-title":"Cannabinoids for the treatment of dementia","author":"Krishnan","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bcp.2018.08.016_b0545","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/01.WNL.0000140706.52798.BE","article-title":"Incidence of parkinsonism and Parkinson disease in a general population the Rotterdam Study","volume":"63","author":"de Lau","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2018.08.016_b0550","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2018.08.016_b0555","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","article-title":"Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease","volume":"132","author":"Bastide","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bcp.2018.08.016_b0560","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s13311-013-0234-1","article-title":"Animal models of parkinson\u2019s disease a gateway to therapeutics?","volume":"11","author":"Le","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bcp.2018.08.016_b0565","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0024-3205(99)00293-3","article-title":"Motor actions of cannabinoids in the basal ganglia output nuclei","volume":"65","author":"Sa\u00f1udo-Pe\u00f1a","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2018.08.016_b0570","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0306-4522(97)00436-3","article-title":"Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system","volume":"83","author":"Tsou","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.016_b0575","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/mds.23457","article-title":"Homeostatic changes of the endocannabinoid system in Parkinson\u2019s disease","volume":"26","author":"Pisani","year":"2010","journal-title":"Mov Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0580","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/7268","article-title":"Dopamine activation of endogenous cannabinoid signaling in dorsal striatum","volume":"2","author":"Giuffrida","year":"1999","journal-title":"Nat Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0585","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1073\/pnas.0510797103","article-title":"Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling","volume":"103","author":"Yin","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2018.08.016_b0590","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0278-5846(00)00119-6","article-title":"Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain","volume":"24","author":"Melis","year":"2000","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2018.08.016_b0595","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1523\/JNEUROSCI.0529-04.2004","article-title":"Cannabinoids enhance subsecond dopamine release in the nucleus Accumbens of awake rats","volume":"24","author":"Cheer","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0600","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro relevance to Parkinson\u2019s disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0605","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3940(99)00762-4","article-title":"Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats","volume":"276","author":"Zeng","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b0610","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0024-3205(99)00618-9","article-title":"Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen","volume":"66","author":"Romero","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2018.08.016_b0615","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.brainresbull.2010.01.009","article-title":"Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson\u2019s disease in the rat","volume":"81","author":"Walsh","year":"2010","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.bcp.2018.08.016_b0620","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1046\/j.0953-816x.2001.01812.x","article-title":"Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson\u2019s syndrome and of MPTP-treated marmosets","volume":"14","author":"Lastres-Becker","year":"2001","journal-title":"Eur. J .Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0625","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.nbd.2018.06.019","article-title":"The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing\/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia","volume":"118","author":"Rojo-Bustamante","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0630","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0635","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease","volume":"19","author":"van der Stelt","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2018.08.016_b0640","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00702-003-0033-7","article-title":"Expression of cannabinoid CB 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain","volume":"110","author":"Hurley","year":"2003","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.bcp.2018.08.016_b0645","first-page":"1","article-title":"Cannabinoid CB1 and CB2 Receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson\u2019s disease","author":"Navarrete","year":"2018","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.bcp.2018.08.016_b0650","article-title":"Regional changes in type 1 cannabinoid receptor availability in Parkinson\u2019s disease in vivo","volume":"33","author":"Van Laere","year":"2012","journal-title":"NBA."},{"key":"10.1016\/j.bcp.2018.08.016_b0655","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/mds.23014","article-title":"Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson\u2019s disease patients","volume":"25","author":"Pisani","year":"2010","journal-title":"Mov Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0660","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/42015","article-title":"A second endogenous cannabinoid that modulates long-term potentiation","volume":"388","author":"Stella","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.08.016_b0665","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2005.11.035","article-title":"Cannabinoid CB2 receptors Immunohistochemical localization in rat brain","volume":"1071","author":"Gong","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2018.08.016_b0670","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881110367732","article-title":"Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis","volume":"25","author":"Lanciego","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0675","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00429-014-0823-8","article-title":"Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques changes following experimental parkinsonism","volume":"220","author":"Sierra","year":"2015","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.bcp.2018.08.016_b0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2014.12.003","article-title":"Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson\u2019s disease","volume":"587","author":"Garc\u00eda","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b0685","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","article-title":"Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson\u2019s disease","volume":"64","author":"G\u00f3mez-G\u00e1lvez","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2018.08.016_b0690","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology."},{"key":"10.1016\/j.bcp.2018.08.016_b0695","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00401-007-0244-3","article-title":"Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson\u2019s disease","volume":"114","author":"Braak","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bcp.2018.08.016_b0700","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2015.04.007","article-title":"Differential upregulation of the cannabinoid CB(2) receptor in neurotoxic and inflammation-driven rat models of Parkinson\u2019s disease","volume":"269","author":"Concannon","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b0705","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.expneurol.2016.06.014","article-title":"Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson\u2019s disease","volume":"283","author":"Concannon","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b0710","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1460-9568.2009.06764.x","article-title":"WIN55,212\u20132, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"29","author":"Price","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0715","first-page":"269","article-title":"Behavioral methods in cannabinoid research","volume":"123","author":"Fride","year":"2006","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.bcp.2018.08.016_b0720","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.nbd.2004.10.015","article-title":"Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism","volume":"18","author":"Fernandez-Espejo","year":"2005","journal-title":"Neurobiol Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0725","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.brainres.2005.12.014","article-title":"Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson\u2019s disease","volume":"1073\u20131074","author":"Gonz\u00e1lez","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2018.08.016_b0730","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson\u2019s disease","volume":"163","author":"Garcia","year":"2011","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0735","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130100728","article-title":"Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates","volume":"156","author":"Meschler","year":"2001","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0740","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0304-3940(98)00368-1","article-title":"Cannabinoid effects in basal ganglia in a rat model of Parkinson\u2019s disease","volume":"248","author":"Sa\u00f1udo-Pe\u00f1a","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b0745","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/sj.npp.1300407","article-title":"Experimental parkinsonism alters anandamide precursor synthesis and functional deficits are Improved by AM404 a modulator of endocannabinoid function","volume":"29","author":"Fernandez-Espejo","year":"2004","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bcp.2018.08.016_b0750","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.euroneuro.2007.11.003","article-title":"Therapeutic effects of \u03949-THC and modafinil in a marmoset Parkinson model","volume":"18","author":"van Vliet","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0755","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1471-4892(02)00011-5","article-title":"CB1 cannabinoid receptor signalling in Parkinson\u2019s disease","volume":"3","author":"Brotchie","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0760","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.tibs.2015.07.007","article-title":"Structures for G-Protein-coupled receptor tetramers in complex with G proteins","volume":"40","author":"Cordom\u00ed","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2018.08.016_b0765","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garcia-Arencibia","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2018.08.016_b0770","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1038\/emm.2015.100","article-title":"CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson\u2019s disease","volume":"48","author":"Chung","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bcp.2018.08.016_b0775","doi-asserted-by":"crossref","first-page":"67837","DOI":"10.18632\/oncotarget.18871","article-title":"AM1241 alleviates MPTP-induced Parkinson\u2019s disease and promotes the regeneration of DA neurons in PD mice","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.bcp.2018.08.016_b0780","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fnins.2016.00321","article-title":"Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson\u2019s disease","volume":"10","author":"Javed","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0785","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1073\/pnas.152334899","article-title":"Brain monoglyceride lipase participating in endocannabinoid inactivation","volume":"99","author":"Dinh","year":"2002","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"10.1016\/j.bcp.2018.08.016_b0790","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.08.016_b0795","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.neurobiolaging.2014.05.021","article-title":"The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model","volume":"35","author":"Fern\u00e1ndez-Su\u00e1rez","year":"2014","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.bcp.2018.08.016_b0800","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1007\/s12035-015-9213-3","article-title":"Neuroprotective effect of JZL184 in MPP+-Treated SH-SY5Y cells through CB2 receptors","volume":"53","author":"Aymerich","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2018.08.016_b0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2016.06.010","article-title":"Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson\u2019s disease","author":"Celorrio","year":"2016","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.bcp.2018.08.016_b0810","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nature05506","article-title":"Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson\u2019s disease models","volume":"445","author":"Kreitzer","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.08.016_b0815","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","article-title":"GPR55 A therapeutic target for Parkinson\u2019s disease?","volume":"125","author":"Celorrio","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b0820","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.bjp.0707423","article-title":"Cannabinoids go nuclear evidence for activation of peroxisome proliferator-activated receptors","volume":"152","author":"O\u2019Sullivan","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0825","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.bbrc.2016.08.043","article-title":"Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders","volume":"483","author":"Agarwal","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2018.08.016_b0830","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2174\/092986710790980014","article-title":"From surface to nuclear receptors the endocannabinoid family extends its assets","volume":"17","author":"Pistis","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2018.08.016_b0835","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-018-1060-5","article-title":"Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson\u2019s disease possible involvement of different binding sites at the PPAR\u03b3 receptor","volume":"15","author":"Garc\u00eda","year":"2018","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.bcp.2018.08.016_b0840","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2018.08.016_b0845","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease a randomized double-blind crossover study","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2018.08.016_b0850","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0000000000000016","article-title":"Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease an open-label observational study","volume":"37","author":"Lotan","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0855","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.53.5.436","article-title":"Marijuana for parkinsonian tremor","volume":"53","author":"Frankel","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bcp.2018.08.016_b0860","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/mds.20111","article-title":"Survey on cannabis use in Parkinson\u2019s disease subjective improvement of motor symptoms","volume":"19","author":"Venderov\u00e1","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0865","doi-asserted-by":"crossref","first-page":"874849","DOI":"10.1155\/2015\/874849","article-title":"Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson\u2019s disease patients in colorado","volume":"2015","author":"Finseth","year":"2015","journal-title":"Evid. Based. Complement. Alternat. Med."},{"key":"10.1016\/j.bcp.2018.08.016_b0870","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/WNF.0000000000000246","article-title":"Medical Cannabis in parkinson disease","volume":"40","author":"Balash","year":"2017","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0875","doi-asserted-by":"crossref","first-page":"24845","DOI":"10.1074\/jbc.M114.557025","article-title":"Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons","volume":"289","author":"Laprairie","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.08.016_b0880","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/mol.111.074013","article-title":"Functional selectivity in CB(2) cannabinoid receptor signaling and regulation implications for the therapeutic potential of CB(2) ligands","volume":"81","author":"Atwood","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0885","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/sj.npp.1301375","article-title":"Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids","volume":"32","author":"Carriba","year":"2007","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.bcp.2018.08.016_b0890","doi-asserted-by":"crossref","first-page":"20851","DOI":"10.1074\/jbc.M111.335273","article-title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain","volume":"287","author":"Call\u00e9n","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2018.08.016_b0895","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Clin Neuropharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0900","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.25996","article-title":"Chorea associated with Huntington\u2019s disease To treat or not to treat?","volume":"29","author":"Jankovic","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0905","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-801893-4.00006-7","article-title":"Cognitive and behavioral changes in Huntington disease before diagnosis","author":"Paulsen","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b0910","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bpa.12426","article-title":"Huntington\u2019s disease (HD) the neuropathology of a multisystem neurodegenerative disorder of the human brain","volume":"26","author":"R\u00fcb","year":"2016","journal-title":"Brain Pathol."},{"key":"10.1016\/j.bcp.2018.08.016_b0915","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/B978-0-12-801893-4.00002-X","article-title":"Mechanisms underlying neurodegeneration in Huntington disease applications to novel disease-modifying therapies","volume":"144","author":"Ross","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b0920","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.parkreldis.2014.12.013","article-title":"Update on Huntington\u2019s disease advances in care and emerging therapeutic options","volume":"21","author":"Zielonka","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0925","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-3-642-45106-5_14","article-title":"Huntington\u2019s disease","volume":"220","author":"Zuccato","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b0930","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.26006","article-title":"Animal models of Huntington\u2019s disease for translation to the clinic Best practices","volume":"29","author":"Menalled","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0935","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/mds.26021","article-title":"Clinical trials in Huntington\u2019s disease. Interventions in early clinical development and newer methodological approaches","volume":"29","author":"Sampaio","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0940","doi-asserted-by":"crossref","DOI":"10.1002\/mds.27363","article-title":"Huntington\u2019s disease Current and future therapeutic prospects","author":"Kieburtz","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0945","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/1568007033482751","article-title":"The endocannabinoid system and Huntington\u2019s disease","volume":"2","author":"Lastres-Becker","year":"2003","journal-title":"Curr. Drug Targets. CNS Neurol. Disord."},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2018.08.016_b0950","first-page":"23","article-title":"Cannabis in movement disorders","volume":"6","author":"M\u00fcller-Vahl","year":"1999","journal-title":"Forsch. Komplementarmed."},{"key":"10.1016\/j.bcp.2018.08.016_b0955","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington\u2019s disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2018.08.016_b0960","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","article-title":"Nabilone increases choreatic movements in Huntington\u2019s disease","volume":"14","author":"M\u00fcller-Vahl","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0965","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in Huntington\u2019s disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b0970","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b0975","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease","volume":"263","author":"L\u00f3pez-Send\u00f3n Moreno","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b0980","first-page":"1","article-title":"Cannabinoids for treatment of dystonia in Huntington\u2019s","author":"Saft","year":"2018","journal-title":"Disease, J. Huntingtons. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b0985","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington\u2019s disease a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.016_b0990","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","article-title":"Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington\u2019s disease","volume":"929","author":"Lastres-Becker","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2018.08.016_b0995","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","article-title":"Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington\u2019s disease","volume":"163","author":"Dowie","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.016_b1000","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.neurobiolaging.2014.06.010","article-title":"Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6\/2 Huntington mice","volume":"35","author":"Ooms","year":"2014","journal-title":"Neurobiol. Aging."},{"key":"10.1016\/j.bcp.2018.08.016_b1005","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/dds037","article-title":"Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice","volume":"21","author":"Pouladi","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2018.08.016_b1010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainresbull.2006.11.004","article-title":"The Hdh(Q150\/Q150) knock-in mouse model of HD and the R6\/2 exon 1 model develop comparable and widespread molecular phenotypes","volume":"72","author":"Woodman","year":"2007","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bcp.2018.08.016_b1015","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.neuropharm.2006.06.013","article-title":"The cannabinoid receptor agonist WIN 55,212\u20132 attenuates the effects induced by quinolinic acid in the rat striatum","volume":"51","author":"Pintor","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b1020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease","volume":"134","author":"Bl\u00e1zquez","year":"2011","journal-title":"Brain."},{"key":"10.1016\/j.bcp.2018.08.016_b1025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jneuroim.2013.12.008","article-title":"The cytokine and endocannabinoid systems are co-regulated by NF-\u03baB p65\/RelA in cell culture and transgenic mouse models of Huntington\u2019s disease and in striatal tissue from Huntington\u2019s disease patients","volume":"267","author":"Laprairie","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2018.08.016_b1030","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1097\/00001756-200410250-00015","article-title":"Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo","volume":"15","author":"Lastres-Becker","year":"2004","journal-title":"NeuroReport"},{"key":"10.1016\/j.bcp.2018.08.016_b1035","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.nbd.2011.12.017","article-title":"Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington\u2019s disease","volume":"45","author":"Chiodi","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b1040","doi-asserted-by":"crossref","first-page":"8257","DOI":"10.1073\/pnas.1400988111","article-title":"A restricted population of CB1 cannabinoid receptors with neuroprotective activity","volume":"111","author":"Chiarlone","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2018.08.016_b1045","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","author":"Fern\u00e1ndez-Ruiz","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b1050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/cercor\/bhx285","article-title":"Pathway-specific control of striatal neuron vulnerability by corticostriatal cannabinoid CB1 receptors","volume":"28","author":"Ruiz-Calvo","year":"2018","journal-title":"Cereb. Cortex."},{"key":"10.1016\/j.bcp.2018.08.016_b1055","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity relevance for Huntington\u2019s disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.bcp.2018.08.016_b1060","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2018.08.016_b1065","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","article-title":"Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease","volume":"32","author":"Bouchard","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b1070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jchemneu.2014.06.004","article-title":"Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington\u2019s disease brain","volume":"59\u201360","author":"Dowie","year":"2014","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.bcp.2018.08.016_b1075","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/00001756-200107200-00017","article-title":"Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington\u2019s disease","volume":"12","author":"Lastres-Becker","year":"2001","journal-title":"NeuroReport"},{"key":"10.1016\/j.bcp.2018.08.016_b1080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuint.2007.06.031","article-title":"Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6\/2 mice, a transgenic model of Huntington\u2019s disease","volume":"52","author":"Bisogno","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bcp.2018.08.016_b1085","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1111\/febs.12329","article-title":"In vitro and in vivo models of Huntington\u2019s disease show alterations in the endocannabinoid system","volume":"280","author":"Bari","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2018.08.016_b1090","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2007.04.012","article-title":"Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington\u2019s disease mutation in peripheral lymphocytes","volume":"27","author":"Battista","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b1095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/157488912798842278","article-title":"Cannabinoids novel medicines for the treatment of Huntington\u2019s disease","volume":"7","author":"Sagredo","year":"2012","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.bcp.2018.08.016_b1100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nbd.2014.08.009","article-title":"Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice","volume":"71","author":"Naydenov","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b1105","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.nbd.2011.03.006","article-title":"Worsening of Huntington disease phenotype in CB1 receptor knockout mice","volume":"42","author":"Mievis","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b1110","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.neuropharm.2014.07.021","article-title":"Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington\u2019s disease","volume":"89","author":"Pietropaolo","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b1115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","article-title":"Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington\u2019s disease transgenic mice","volume":"170","author":"Dowie","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.08.016_b1120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b1125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","article-title":"Neuroprotective properties of cannabigerol in Huntington\u2019s disease studies in R6\/2 mice and 3-nitropropionate-lesioned mice","volume":"12","author":"Valdeolivas","year":"2015","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.bcp.2018.08.016_b1130","doi-asserted-by":"crossref","first-page":"29789","DOI":"10.1038\/srep29789","article-title":"VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington\u2019s disease","volume":"6","author":"D\u00edaz-Alonso","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2018.08.016_b1135","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","article-title":"Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease role of CB1 and CB2 receptors","volume":"3","author":"Valdeolivas","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b1140","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington\u2019s disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bcp.2018.08.016_b1145","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3390\/ijms18040684","article-title":"Effects of a sativex-like combination of phytocannabinoids on disease progression in R6\/2 Mice, an experimental model of Huntington\u2019s disease","volume":"18","author":"Valdeolivas","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2018.08.016_b1150","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/nbdi.1998.0220","article-title":"Brain cannabinoid systems as targets for the therapy of neurological disorders","volume":"5","author":"Consroe","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b1155","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/ene.13349","article-title":"Clinical characterization of dystonia in adult patients with Huntington\u2019s disease","volume":"24","author":"van de Zande","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b1160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b1165","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrneurol.2013.203","article-title":"The epidemiology of ALS a conspiracy of genes, environment and time","volume":"9","author":"Al-Chalabi","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b1170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 Is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2018.08.016_b1175","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026757","article-title":"The genetics of C9orf72 expansions","volume":"8","author":"Gijselinck","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bcp.2018.08.016_b1180","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.15252\/embj.201797568","article-title":"Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder","volume":"36","author":"Gao","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2018.08.016_b1185","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tins.2013.04.010","article-title":"Current insights into the C9orf72 repeat expansion diseases of the FTLD\/ALS spectrum","volume":"36","author":"Cruts","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b1190","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/ars.2009.2444","article-title":"Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis","volume":"11","author":"Foran","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bcp.2018.08.016_b1195","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrneurol.2011.152","article-title":"Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis","volume":"7","author":"Ferraiuolo","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b1200","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nbd.2017.02.004","article-title":"Neurobiology of axonal transport defects in motor neuron diseases opportunities for translational research?","volume":"105","author":"De Vos","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2018.08.016_b1205","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1242\/dmm.029058","article-title":"Modelling amyotrophic lateral sclerosis progress and possibilities","volume":"10","author":"Van Damme","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bcp.2018.08.016_b1210","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/14728214.2011.604312","article-title":"Emerging drugs for amyotrophic lateral sclerosis","volume":"16","author":"Habib","year":"2011","journal-title":"Expert Opin. Emerg. Drugs."},{"key":"10.1016\/j.bcp.2018.08.016_b1215","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","article-title":"ALS clinical trials review 20 years of failure. Are we any closer to registering a new treatment?","volume":"9","author":"Petrov","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b1220","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1049909110369531","article-title":"Cannabis and amyotrophic lateral sclerosis hypothetical and practical applications, and a call for clinical trials","volume":"27","author":"Carter","year":"2010","journal-title":"Am. J. Hosp. Palliat. Care."},{"key":"10.1016\/j.bcp.2018.08.016_b1225","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.expneurol.2010.03.030","article-title":"The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis","volume":"224","author":"Rossi","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b1230","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/j.1471-4159.2004.02544.x","article-title":"Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice","volume":"89","author":"Witting","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2018.08.016_b1235","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1096\/fj.05-4743fje","article-title":"Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice","volume":"20","author":"Bilsland","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2018.08.016_b1240","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/cns.12262","article-title":"Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1 G93A transgenic mice and evaluation of a Sativex \u00ae -like combination of phytocannabinoids interest for future therapies in amyotrophic lateral sclerosis","volume":"20","author":"Moreno-Martet","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bcp.2018.08.016_b1245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuropharm.2017.03.037","article-title":"Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS","volume":"124","author":"Pasquarelli","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.08.016_b1250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1471-4159.2006.04346.x","article-title":"The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset","volume":"101","author":"Shoemaker","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2018.08.016_b1255","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11481-015-9602-4","article-title":"Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice relevance for a neuroprotective therapy in TDP-43-related disorders","volume":"10","author":"Espejo-Porras","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b1260","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1242\/dmm.028373","article-title":"Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis","volume":"10","author":"Fern\u00e1ndez-Trapero","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bcp.2018.08.016_b1265","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b1270","first-page":"1","article-title":"Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients","author":"Espejo-Porras","year":"2018","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"10.1016\/j.bcp.2018.08.016_b1275","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1460-9568.2008.06041.x","article-title":"Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice implications for excitotoxicity","volume":"27","author":"Zhao","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2018.08.016_b1280","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ana.24304","article-title":"Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice","volume":"77","author":"Butovsky","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2018.08.016_b1285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14660820310016813","article-title":"Amyotrophic lateral sclerosis delayed disease progression in mice by treatment with a cannabinoid, Amyotroph","volume":"5","author":"Raman","year":"2004","journal-title":"Lateral Scler. Other Mot. Neuron Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b1290","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/14660820510030149","article-title":"Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival","volume":"6","author":"Weydt","year":"2005","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord."},{"key":"10.1016\/j.bcp.2018.08.016_b1295","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2006.05.025","article-title":"AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis","volume":"542","author":"Kim","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b1300","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14216","article-title":"Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis","author":"Espejo-Porras","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.016_b1305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/104990910402100206","article-title":"Survey of cannabis use in patients with amyotrophic lateral sclerosis","volume":"21","author":"Amtmann","year":"2004","journal-title":"Am. J. Hosp. Palliat. Med."},{"key":"10.1016\/j.bcp.2018.08.016_b1310","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2009.200642","article-title":"Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis a randomised, double-blind crossover trial","volume":"81","author":"Weber","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.bcp.2018.08.016_b1315","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1872312811206020102","article-title":"Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis","volume":"6","author":"Joerger","year":"2012","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.bcp.2018.08.016_b1320","doi-asserted-by":"crossref","unstructured":"E. de Lago, M. Moreno-Martet, F. Espejo-Porras, F. Fern\u00e1ndez-Ruiz, Endocannabinoids and amyotrophic lateral sclerosis, F. L (Ed.), Cannabinoids Neurol. Ment. Dis., Elsevier, 2015 pp. 99\u2013124.","DOI":"10.1016\/B978-0-12-417041-4.00005-9"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629521830337X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629521830337X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T22:59:12Z","timestamp":1604789952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629521830337X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":264,"alternative-id":["S000629521830337X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.08.016","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}